Q1 EPS Estimates for Nuvation Bio Lowered by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Investment analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Nuvation Bio in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.17) per share for the quarter, down from their prior forecast of ($0.15). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.71) EPS.

A number of other brokerages have also recently commented on NUVB. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Wedbush reissued an “outperform” rating and issued a $5.00 price objective on shares of Nuvation Bio in a research note on Monday, March 3rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Nuvation Bio currently has a consensus rating of “Buy” and an average price target of $8.00.

Nuvation Bio Stock Up 22.6 %

NYSE:NUVB opened at $2.31 on Wednesday. Nuvation Bio has a fifty-two week low of $1.67 and a fifty-two week high of $4.16. The stock has a market cap of $775.79 million, a PE ratio of -1.06 and a beta of 1.47. The firm’s fifty day simple moving average is $2.39 and its 200-day simple moving average is $2.57.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in Nuvation Bio by 4.8% in the 3rd quarter. State Street Corp now owns 4,166,441 shares of the company’s stock valued at $9,541,000 after purchasing an additional 191,031 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Nuvation Bio by 83.3% during the 3rd quarter. Wellington Management Group LLP now owns 623,973 shares of the company’s stock worth $1,429,000 after acquiring an additional 283,642 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Nuvation Bio by 5.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,028,692 shares of the company’s stock worth $9,227,000 after acquiring an additional 196,247 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Nuvation Bio by 479.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 442,913 shares of the company’s stock worth $1,014,000 after acquiring an additional 366,429 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in shares of Nuvation Bio during the 3rd quarter worth about $634,000. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.